Search
Current & Future Options for COVID-19
Gilotrif-LongForm.pdf
Glyxambi-LongForm.pdf
Jardiance-LongForm.pdf
Jentadueto-LongForm.pdf
Ofev-LongForm.pdf
Pradaxa-LongForm.pdf
synjardy-XR-LongForm.pdf
Tradjenta-LongForm.pdf
Trijardy-XR-LongForm.pdf
biah-us-overview-for-usda
Synjardy® (empagliflozin/metformin) Factsheet | PDF
PAP Program Sales Force Info Flashcard
Spanish-Enrollment-Form_0.pdf
EDITABLE-Spanish-Enrollment-form_3.pdf
Cancer
Cancer
Marie Penzold
Marie Penzold talks about her career as a HR business partner in the Innovation unit here at Boehringer Ingelheim.
Promising Phase II Results in Chronic Kidney Disease
Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
Digital solutions save lives
Digital solutions save lives
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer included on LinkedIn’s “Top Companies 2024” list
Investing in our people is at the core of what we do
Clinical Studies
Clinical Studies
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund